ED50 and ED95 of Isobaric Bupivacaine for Post-Partum Bilateral Tubal Ligation



Status:Recruiting
Healthy:No
Age Range:18 - 65
Updated:3/1/2019
Start Date:February 25, 2019
End Date:December 1, 2019
Contact:Nwamaka Nnamani, MD
Email:nwamaka.nnamani@utsouthwestern.edu
Phone:214-645-7011

Use our guide to learn which trials are right for you!

Determination of ED50 and ED95 of Isobaric Bupivacaine for Post-Partum Bilateral Tubal Ligation

Spinal anesthesia is one of the preferred anesthetic techniques for post-partum bilateral
tubal ligation (PBTL). Bupivacaine is the most commonly used local anesthetic for neuraxial
anesthesia for post-partum tubal ligation. Typically, hyperbaric bupivacaine would be
injected into the spinal (intrathecal) space via a spinal needle; however, ongoing medication
shortages have resulted in limited availability on a local and national level. One proposed
alternative is isobaric bupivacaine; however, studies investigating its use for post-partum
bilateral tubal ligation are limited.

The purpose of this prospective study is to determine the minimal effective dose (ED50 and
ED95) of isobaric bupivacaine for adequate anesthesia during post-partum tubal ligation after
vaginal delivery.

This prospective study proposes to enroll 40 post-partum women who are undergoing elective
post-partum bilateral tubal ligation. The patient will be positioned sitting, and combined
spinal anesthesia will be performed at L2-3 or L3-4 level. The presence of an epidural
catheter enables the provider to supplement the spinal anesthetic if required. The starting
dose of isobaric bupivacaine will be 10 mg based on prior similar studies1,4 and our
institution's current practice. The dose of intrathecal isobaric bupivacaine was decided by
using the up-down sequential method.

The motor block will be graded by a modified Bromage score: Score 1 = complete block, unable
to move feet or knees; 2 = almost complete block, able to move feet only; 3 = partial block,
just able to move knees; 4 = detectable weakness of hip flexion while supine, full flexion of
knees; 5 = no detectable weakness of hip flexion while supine; and 6 = able to perform
partial knee bend. The score of 1 or 2 within 10-15 minutes of injection will be evaluated as
successful motor block.

The success of the sensory spinal block will be noted when bilateral T6 sensory level to
pinprick is attained after 10 mins from the intrathecal drug administration, this is in
accordance with previous studies1.

If spinal anesthesia is inadequate, the epidural catheter will be dosed up for
supplementation. All observations, including block characteristics and the associated outcome
(i.e., adequate or inadequate block), will be evaluated by a dedicated anesthesia provider.

Intraoperative adverse effects, such as hypotension, bradycardia, nausea, or vomiting,
pruritus, or shivering were noted. Hypotension is defined as a decrease of more than 20% in
basal systolic blood pressure within 30 minutes of intrathecal injection. The management of
blood pressure including dose of pressor: phenylephrine and ephedrine will be at the
discretion of the attending anesthesiologist. The use of pressor and anti-emetics will also
be recorded.

The study will be take place in standard clinical context. The study does not deviate from
our current practice, which includes the use of combined spinal anesthesia where the epidural
catheter is available if supplemental local anesthetic is required.

Inclusion Criteria:

- Age 18 and older

- Patients undergoing elective post-partum bilateral tubal ligation after vaginal
delivery

- Patients receiving spinal epidural anesthesia with combination of bupivacaine and
fentanyl

Exclusion Criteria:

- American Society of Anesthesiologists physical status score >3,

- Contraindications to neuraxial analgesia

- Patients in whom a combined spinal epidural cannot be performed

- Body mass index >40 kg/m2

- Allergy or hypersensitivity to local anesthetics and fentanyl

- Severe liver, kidney or respiratory disease.

- Inability to understand the study protocol

- Refusal to provide written consent
We found this trial at
1
site
Dallas, Texas 75390
Phone: 214-786-7973
?
mi
from
Dallas, TX
Click here to add this to my saved trials